Glucocorticosteroids for the treatment and prevention of anaphylaxis

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 3, 2013, Pages 263-267

  Sheikh, Aziz ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

anaphylaxis; glucocorticosteroids; management; prevention; randomized controlled trials

Indexed keywords

GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; OMALIZUMAB; PREDNISOLONE; SNAKE VENOM ANTISERUM;

ANAPHYLAXIS; CLINICAL TRIAL; DISEASE SEVERITY; HUMAN; IMMUNOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SNAKEBITE; SYSTEMATIC REVIEW;

ALLERGENS; ANAPHYLAXIS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EPINEPHRINE; GLUCOCORTICOIDS; HISTAMINE ANTAGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TREATMENT OUTCOME;

EID: 84876889770     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32836097f4     Document Type: Review

References (29)

1. Gibbison B, Sheikh A, McShane P, et al. Anaphylaxis admissions to UK critical care units between 2005 and 2009. Anaesthesia 2012; 67:833-839.
2. Simons FER, Ardusso LRF, Bilo MB, et al. World Allergy Organization guidelines: summary. J Allergy Clin Immunol 2011; 127:587-593; e1-e22.
3. Simons FE, Ardusso LR, Bilò MB, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012; 12:389-399.
4. Beyer K, Eckermann O, Hompes S, et al. Anaphylaxis inan emergency setting: elicitors, therapy and incidence of severe allergic reactions. Allergy 2012; 67:1451-1456.
5. Sheikh A, Smeeth L, Ashcroft R. Randomised controlled trials in primary care: scope and application. Br J Gen Pract 2002; 52:746-751. (Pubitemid 36187599)
6. Cochrane AL. Effectiveness and efficiency: random reflections on health services. London: Royal Society of Medicine Press Ltd; 1999.
7. Simons FE, Sheikh A. Evidence-based management of anaphylaxis. Allergy 2007; 62:827-829. (Pubitemid 47037862)
8. Simons FE. Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened? Curr Opin Allergy Clin Immunol 2010; 10:384-393.
9. Tanno LK, Ganem F, Demoly P, et al. Undernotification of anaphylaxis deaths in Brazil due to difficult coding under the ICD-10. Allergy 2012; 67:783-789.
10. Pumphrey RSH. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144-1150. (Pubitemid 30619768)
11. Charmandari E, Johnston A, Brook CG, Hindmarsh PC. Bioavailability of oral hydrocortisone in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Endocrinol 2001; 169:65-70. (Pubitemid 32273215)
12. Alrasbi M, Sheikh A. Comparison of international guidelines for the emergency medical management of anaphylaxis. Allergy 2007; 62:838-841. (Pubitemid 47037863)
13. Choo KJ, Simons FE, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Rev 2010; 3:CD007596.
14. Choo KJL, Simons FER, Sheikh A. Glucocorticoids for the treatment of anaphylaxis. Cochrane Database Syst Review 2012; 4:CD007596.
15. Tramèr MR, von Elm E, Loubeyre P, Hauser C. Pharmacological prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review. Br Med J 2006; 333:675.
16. Habib AG. Effect of premedication on early adverse reactions following antivenom use in snakebite: a systematic review and meta-analysis. Drug Saf 2011; 34:869-880.
17. de Silva AH, Pathmeswaran A, Ranasinha CD, et al. Low-dose adrenaline, promethazine, and hydrocortisone in the prevention of acute adverse reactions to antivenom following snakebite: a randomised, double-blind, placebo-controlled trial. PLoS Med 2011; 8:e1000435.
18. Calderón MA, Boyle RJ, Penagos M, Sheikh A. Immunotherapy: the meta-analyses. What have we learned? Immunol Allergy Clin North Am 2011; 31:159-173.
19. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev 2011; 6:CD007685. Key systematic review on sublingual immunotherapy for allergic conjunctivitis.
20. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8:CD001186.
21. Nurmatov U, Venderbosch I, Devereux G, et al. Allergen-specific oral immuno-therapy for peanut allergy. Cochrane Database Syst Rev 2012; 9:CD009014.
22. Sheikh A, Nurmatov U, Venderbosch I, Bischoff E. Oral immunotherapy for the treatment of peanut allergy: systematic review of six case series studies. Prim Care Respir J 2012; 21:41-49.
23. Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev 2012; 17:CD008838.
24. Portnoy J, Bagstad K, Kanarek H, et al. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts. Ann Allergy 1994; 73:409-418. (Pubitemid 24368195)
25. Tankersley MS, Walker RL, Butler WK, et al. Safety and efficacy of an imported fire ant rush immunotherapy protocol with and without prophylactic treatment. J Allergy Clin Immunol 2002; 109:556-562. (Pubitemid 34234210)
26. Calderon MA, Demoly P, Gerth van Wijk R, et al. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy 2012; 2:20.
27. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364:1005-1015.
28. Shankar T, Petrov AA. Omalizumab and hypersensitivity reactions. Curr Opin Allergy Clin Immunol 2013; 13:19-24.
29. Thomson NC, Chaudhuri R. Omalizumab: clinical use for the management of asthma. Clin Med Insights Circ Respir Pulm Med 2012; 6: 27-40.